Lapatinib side-effect management

Clinical Journal of Oncology Nursing

Volumn 14, Issue 2, 2010, Pages 223-233

  Frankel, Cynthia ^a   Palmieri, Frances M ^b  

^a Memorial Healthcare System   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LAPATINIB; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

CHEMICALLY INDUCED DISORDER; DIARRHEA; DRUG ANTAGONISM; HUMAN; PARONYCHIA; REVIEW; SKIN DISEASE;

ANTINEOPLASTIC AGENTS; DIARRHEA; HUMANS; PARONYCHIA; PROTEIN-TYROSINE KINASES; QUINAZOLINES; SKIN DISEASES;

EID: 77955298667     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.223-233     Document Type: Review

References (48)

1. Agero, A.L., Dusza, S.W., Benvenuto-Andrade, C., Busam, K.J., Myskowski, P., & Halpern, A.C. (2006). Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 55, 657-670. doi: 10.1016/j.jaad.2005.10.010
2. Arbuckle, R.B., Huber, S.L., & Zacker, C. (2000). The consequences of diarrhea occurring during chemotherapy for colorectal cancer: A retrospective study. Oncologist, 5, 250-259. Retrieved from http://theoncologist.alphamedpress.org/cgi/content/full/5/3/250
3. Arnold, R.J., Gabrail, N., Raut, M., Kim, R., Sung, J.C., & Zhou, Y. (2005). Clinical implications of chemotherapy-induced diarrhea in patients with cancer. Journal of Supportive Oncology, 3, 227-232.
4. ® [Package insert]. Wilmington, DE: Author.
5. Baskerville, A., & Batter-Hatton, D. (1977). Intestinal lesions induced experimentally by methotrexate. British Journal of Experimental Pathology, 58, 663-669.
6. Benson, A.B., III, Ajani, J.A., Catalano, R.B., Engelking, C., Kornblau, S.M., Martenson, J.A., Jr., Wadler, S. (2004). Recommended guidelines for the treatment of cancer treatment-induced diarrhea. Journal of Clinical Oncology, 22, 2918-2926. doi: 10.1200/JCO.2004.04.132
7. ® [Package insert]. Princeton, NJ: Author.
8. Bruno, R., Mass, R.D., & Jones, C. (2003). Preliminary population pharmacokinetics (PPK) and exposure-safety (E-S) relationships of erlotinib HCI in patients with metastatic breast cancer (MBC) [Abstract]. Proceedings of the American Society of Clinical Oncology, 22, 205.
9. Burris, H.A., III, Hurwitz, H.I., Dees, E.C., Dowlati, A., Blackwell, K.L., O'Neil, B., Spector, N.L. (2005). Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Journal of Clinical Oncology, 23, 5305-5313. doi:10.1200/JCO.2005.16.584
10. Burris, H.A., III. (In press). A phase I, open-label study of the safety, tolerability, and pharmacokinetics of lapatinib in combination with paclitaxel in patients with solid tumors. Clinical Cancer Research.
11. Burtness, B., Goldwasser, M.A., Flood, W., Mattar, B., & Forastiere, A.A. (2005). Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. Journal of Clinical Oncology, 23, 8646-8654. doi:10.1200/JCO.2005.02.4646
12. Busam, K.J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., & Halpern, A.C. (2001). Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. British Journal of Dermatology, 144, 1169-1176. doi:10.1046/j.1365-2133.2001.04226.x
13. Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C.G., Geyer, C.E. (2008). A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Research and Treatment, 112, 533-543. doi: 10.1007/s10549-007-9885-0
14. Clarke, G., Perez-Soler, R., & Siu, L. (2003). Rash severity is predictive of increased survival with erlotinib HCI [Abstract]. Proceedings of the American Society of Clinical Oncology, 22, 196.
15. Cristofanilli, M., Boussen, H., Baselga, J., Lluch, A., Ben Ayed, F., & Friaha, M. (2006). A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [Abstract 1]. Breast Cancer Research and Treatment, 100, S5.
16. Crown, J.P., Burris, H.A., III, Boyle, F., Jones, S., Koehler, M., Newstat, B.O., Chan, S. (2008). Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Research and Treatment, 112, 317-325. doi: 10.1007/s10549-007-9860-9
17. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Van Cutsem, E. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine, 351, 337-345. doi: 10.1056/NEJMoa033025
18. Dang, C., Lin, N., Lake, D., Theodoulou, M., Drullinsky, P., & Gorsky, M. (2008). Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BC): First safety results [Abstract 1810]. Annals of Oncology, 19, 877.
19. de Roy van Zuidewijn, D.B., Schillings, P.H., Wobbes, T., Hendriks, T., & de Boer, H.H. (1992). Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats. Experimental and Molecular Pathology, 56, 96-107. doi: 10.1016/0014-4800(92)90027-9
20. Di Leo, A., Gomez, H.L., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M.C., Press, M.F. (2008). Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Journal of Clinical Oncology, 26, 5544-5552. doi: 10.1200/JCO.2008.16.2578
21. Fields, A.L., Rinaldi, D.A., Henderson, C.A., Germond, C.J., Chu, L., & Brill, K.J. (2005). An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer [Abstract]. Journal of Clinical Oncology, 23, 7099.
22. ® [Package insert]. San Francisco, CA: Author.
23. Geyer, C.E., Forster, J., Lindquist, D., Chan, S., Romieu, C.G., Pienkowski, T., Cameron, D. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New England Journal of Medicine, 355, 2733-2743. doi: 10.1056/NEJMoa064320
24. ® [Package insert]. Research Triangle Park, NC: Author.
25. ® [Package insert]. Branchburg, NJ: Author.
26. Johnson, B.S., Dueck, A.C., Dakhil, S.R., Stella, P.J., Nikcevich, D.A., Franco, S.X., Perez, E.A. (2008). Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: Initial safety data from the Mayo Clinic Cancer Research Consortium Trial RC0639. Abstract presented at the 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, TX.
27. Kari, C., Chan, T.O., Rocha de Quadros, M., & Rodeck, U. (2003). Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Research, 63, 1-5. Retrieved from http://cancerres.aacrjournals.org/cgi/content/full/63/1/1
28. Kornblau, S., Benson A.B., Catalano, R., Champlin, R.E., Engelking, C., Field, M., Wadler, S. (2000). Management of cancer treatment-related diarrhea: Issues and therapeutic strategies. Journal of Pain and Symptom Management, 19, 118-129.
29. Lacouture, M.E., Cotliar, J., & Mitchell, E.P. (2007). Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology, 21(11, Suppl. 5), 17-21.
30. Lacouture, M.E., Laabs, S.M., Koehler, M., Sweetman, R.W., Preston, A.J., Di Leo, A., Blackwell, K.L. (2008). Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Research and Treatment, 114, 485-493. doi: 10.1007/s10549-008-0020-7
31. Lacouture, M.E., & Lai, S.E. (2006). The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. British Journal of Dermatology, 155, 852-854. doi:10.1111/j.1365-2133.2006.07452.x
32. National Cancer Institute. (1999). Cancer Therapy Evaluation Program. Common Terminology Criteria [version 2.0]. Retrieved from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf
33. National Cancer Institute. (2006). Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events [version 3.0]. Retrieved from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
34. ® [Package insert]. Melville, NY: Author.
35. Perez-Soler, R. (2006). Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clinical Lung Cancer, 8(Suppl. 1), S7-S14.
36. Perez-Soler, R., Chachoua, A., Hammond, L.A., Rowinsky, E.K., Huberman, M., Karp, D., Bonomi, P. (2004). Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Journal of Clinical Oncology, 22, 3238-3247. doi: 10.1200/JCO.2004.11.057
37. Perez-Soler, R., & Saltz, L. (2005). Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? Journal of Clinical Oncology, 23, 5235-5246. doi: 10.1200/JCO.2005.00.6916
38. Purdom, M., & Ohinata, A. (2007). Clinical management of EGFRI dermatologic toxicities: The nursing perspective. Oncology, 21(11, Suppl. 5), 29-30.
39. Ravaud, A., Gardner, J., Hawkins, R., Von der Maase, H., Zantl, N., Harper, P., El-Hariry, I. (2006). Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC) [Abstract 4502]. Journal of Clinical Oncology, 24(18, Suppl.).
40. ® [Package insert]. Nutley, NJ: Author.
41. Ross, H.J., Blumenschein, G.R., Dowlati, A., Aisner, J., Rigas, J.R., Stanislaus, M., & Leopold, L.H. (2005). Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer [Abstract 7099]. Journal of Clinical Oncology, 23(16, Suppl.).
42. ® [Package insert]. Bridgewater, NJ: Author.
43. Segaert, S., & Van Cutsem, E. (2005). Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of Oncology, 16, 1425-1433. Retrieved from http://annonc.oxfordjournals.org/content/16/9/1425.long
44. Sharma, R., Tobin, P., & Clarke, S.J. (2005). Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncology, 6, 93-102. doi: 10.1016/S1470-2045(05)01735-3
45. Sipples, R. (2006). Common side effects of anti-EGFR therapy: Acneform rash. Seminars in Oncology Nursing, 22(1, Suppl. 1), 28-34. doi: 10.1016/j.soncn.2006.01.013
46. Wadler, S., Haynes, H., & Wiernik, P.H. (1995). Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. Journal of Clinical Oncology, 13, 222-226.
47. Wagner, L.I. & Lacouture, M.E. (2007). Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology, 21(11, Suppl. 5), 34-36.
48. Wülfing, C., Machiels, J.P., Richel, D., Grimm, M.O., Treiber, U., de Groot, M., El-Hariry, I. (2005). A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract [Abstract 4594]. Journal of Clinical Oncology, 23(16, Suppl.).